Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 264 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HPV DNA Clear all
Completed Phase 3 Interventional Results available

Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

NCT01164722
View directory record Official record
Conditions
Anal Cancer, Neoplasm of Uncertain Malignant Potential, Nonneoplastic Condition, Precancerous Condition
Interventions
clinical observation, infrared photocoagulation therapy
Other · Device
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
27 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Jul 22, 2026, 4:59 PM EDT
Completed Not applicable Interventional

A Comparative Study of Occlusive Heat Patch in the Treatment of Warts

NCT01746056
View directory record Official record
Conditions
Verruca (Warts)
Interventions
Occlusive Heat Patch
Device
Lead sponsor
Yale University
Other
Eligibility
5 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Jul 22, 2026, 4:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination

NCT03442062
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Assessment Feedback Incentives and eXchange, Physician-to-physician engagement, Active Intervention Control
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Phoenix, Arizona • Albany, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Jul 22, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer

NCT01084083
View directory record Official record
Conditions
Head and Neck Cancer, Precancerous Condition
Interventions
cetuximab, intensity-modulated radiation therapy (IMRT), Paclitaxel, Cisplatin
Biological · Radiation · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
121
States / cities
Birmingham, Alabama • Greenbrae, California • Palo Alto, California + 86 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jul 22, 2026, 4:59 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

NCT04533750
View directory record Official record
Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oral Cavity Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Peposertib, Positron Emission Tomography
Procedure · Other · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
27
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer

NCT02258659
View directory record Official record
Conditions
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
Interventions
paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, radiation therapy, paclitaxel, fluorouracil, hydroxyurea, cisplatin, laboratory biomarker analysis, quality-of-life assessment
Drug · Radiation · Other + 1 more
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Jul 22, 2026, 4:59 PM EDT
Completed No phase listed Observational Results available

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

NCT05510908
View directory record Official record
Conditions
HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma, AIDS-related Kaposi Sarcoma, AIDS-Related Malignancy, Anal Cancer, HPV-Related Malignancy
Interventions
Non-Interventional, Non-Interventional Follow-up
Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
15
States / cities
La Jolla, California • Washington D.C., District of Columbia • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 22, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts

NCT00735462
View directory record Official record
Conditions
Genital Warts
Interventions
2.5% imiquimod cream, 3.75% imiquimod cream, Placebo cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
43
States / cities
Jonesboro, Arkansas • Carmichael, California • Chico, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Jul 22, 2026, 4:59 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Engaging College Students in Developing and Testing a Video-based Intervention for HPV Vaccination Promotion

NCT06397378
View directory record Official record
Conditions
N/A - Healthy Subjects
Interventions
short videos related to HPV and the HPV vaccine, CDC HPV Fact Sheet
Other
Lead sponsor
Michigan State University
Other
Eligibility
18 Years to 26 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jul 22, 2026, 4:59 PM EDT
Terminated Phase 1 Interventional

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

NCT03677960
View directory record Official record
Conditions
HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer, Anus Neoplasm
Interventions
Topical ABI-1968 cream
Drug
Lead sponsor
Antiva Biosciences
Industry
Eligibility
27 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Jul 22, 2026, 4:59 PM EDT
Active, not recruiting No phase listed Observational

Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer

NCT04574635
View directory record Official record
Conditions
Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Infiltrating Cervical Carcinoma, Metastatic Cervical Carcinoma, Recurrent Cervical Carcinoma, Stage I Cervical Cancer FIGO 2018, Stage IA Cervical Cancer FIGO 2018, Stage IA1 Cervical Cancer FIGO 2018, Stage IA2 Cervical Cancer FIGO 2018, Stage IB Cervical Cancer FIGO 2018, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer FIGO 2018, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018, Stage IIA Cervical Cancer FIGO 2018, Stage IIA1 Cervical Cancer FIGO 2018, Stage IIA2 Cervical Cancer FIGO 2018, Stage IIB Cervical Cancer FIGO 2018, Stage III Cervical Cancer FIGO 2018, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IV Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018, Stage IVB Cervical Cancer FIGO 2018
Interventions
Biospecimen Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Jul 22, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

NCT03603808
View directory record Official record
Conditions
Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
Interventions
Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis
Device · Biological · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Results available

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

NCT01101750
View directory record Official record
Conditions
Cervical Cancer, Hpv, Warts
Interventions
Quadrivalent HPV for types 6, 11, 16 and 18
Biological
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
9 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 22, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Alternate Dosing Schedules Study for HPV Vaccine

NCT00862810
View directory record Official record
Conditions
Cervical Cancer, Genital Warts
Interventions
Received HPV vaccine first, Received concomitant vaccines first
Biological
Lead sponsor
Duke University
Other
Eligibility
9 Years to 18 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Jul 22, 2026, 4:59 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers

NCT01087164
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Compliance, Message sidedness
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
11 Years to 15 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2014 · Synced Jul 22, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

A Phase2 of A-101 Topical Solution in Subjects With Common Warts

NCT03210337
View directory record Official record
Conditions
Common Wart
Interventions
A-101 Topical Solution, A-101 Vehicle Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
8 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Scottsdale, Arizona • Rogers, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Jul 22, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

NCT01209325
View directory record Official record
Conditions
Anal Cancer, Nonneoplastic Condition, Penile Cancer, Precancerous Condition
Interventions
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
13 Years to 26 Years · Male only
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
18
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Jul 22, 2026, 4:59 PM EDT
Recruiting Not applicable Interventional

PCOM2 - The Physician Communication Intervention, Version 2.0

NCT05336240
View directory record Official record
Conditions
HPV Infection, Preventive Health Services
Interventions
Physician Communication 2 Virtual (PCOM2-virtual), Physician Communication Standard (PCOM-standard)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced Jul 22, 2026, 4:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men

NCT00955591
View directory record Official record
Conditions
Anal Cancer, Nonneoplastic Condition, Precancerous Condition
Interventions
Papanicolaou test
Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jul 22, 2026, 4:59 PM EDT
Recruiting Phase 2 Interventional

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

NCT05541016
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Diffusing Alpha-emitter Radiation Therapy, Docetaxel, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Modified Barium Swallow Study, Observation Activity, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire
Procedure · Drug · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 22, 2026, 4:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Self-collected Swabs for HPV Testing in 18-24 Year Old Women

NCT01101828
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 24 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 13, 2011 · Synced Jul 22, 2026, 4:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Prevent Anal Cancer Self-Swab Study

NCT03489707
View directory record Official record
Conditions
Anal Cancer
Interventions
Home-based human papillomavirus (HPV) DNA screening, Clinic-based human papillomavirus (HPV) DNA screening
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
25 Years and older
Enrollment
253 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Jul 22, 2026, 4:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Human Papillomavirus (HPV) Transmission Pilot Study

NCT00823511
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Not listed
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Jul 22, 2026, 4:59 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Offering HPV Self-Collection in Novel Healthcare Settings to Improve Uptake of Cervical Cancer Screening

NCT07186530
View directory record Official record
Conditions
Cervical Carcinoma, Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma
Interventions
Best Practice, Communication Intervention, Electronic Health Record Review, HPV Self-Collection, Standard Follow-Up Care
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 63 Years · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 22, 2026, 4:59 PM EDT